# NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical
Canonical URL: https://biopharmsignal.com/news/NXGL/nexgel-appoints-dave-hazard-as-vice-president-of-sales-for-bionx-surgical
Ticker: NXGL
Company: NEXGEL
Source: NEXGEL
Published: 2026-05-13 12:30 EST
Original Source URL: https://ir.nexgel.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-04 13:00 EST — [NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th](https://biopharmsignal.com/news/NXGL/nexgel-to-present-at-planet-microcap-conference-las-vegas-on-june-16th-18th) — Source: NEXGEL
- 2026-05-19 13:00 EST — [NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration](https://biopharmsignal.com/news/NXGL/nexgel-reports-positive-data-from-randomized-single-center-irb-study-to-evaluate-the-effectiveness-and-safety-of-a-hydrogel-laser-treatment-patch-in-laser-hair-removal-with-a-95-6-reduction-in-plume-concentration) — Source: NEXGEL
- 2026-05-13 12:30 EST — [NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical](https://biopharmsignal.com/news/NXGL/nexgel-appoints-dave-hazard-as-vice-president-of-sales-for-bionx-surgical) — Source: NEXGEL
- 2026-05-12 14:27 EST — [NEXGEL To Report First Quarter 2026 Financial Results on May 15th](https://biopharmsignal.com/news/NXGL/nexgel-to-report-first-quarter-2026-financial-results-on-may-15th) — Source: NEXGEL
- 2026-05-06 13:00 EST — [NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors](https://biopharmsignal.com/news/NXGL/nexgel-appoints-brian-kieser-and-kevin-harris-from-new-strategic-partner-sequence-lifesciencetm-to-board-of-directors) — Source: NEXGEL
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)